Social Media Ideas for Novo Nordisk Foundation

<![CDATA[Novo Nordisk Rebranding to'Novo' ]]>

Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day Transcript

Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand]]>

Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by 2035. The post Novo’s pipeline in 2026: A new plan to re...

FDA extends review for Novo Nordisk's denecimig for hemophilia A

<![CDATA[Pharmaceutical Executive Daily: Novo Partners with Anthropic]]>

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

Novo Nordisk Foundation Postdoctoral Fellowships at MIT 2027: Up to DKK 3.6 Million for Early-Career Researchers

The Novo Nordisk Foundation Postdoctoral Fellowships at Massachusetts Institute of Technology (MIT) 2027 offer an opportunity for early-career researchers to undertake interdiscipl...

Novo Nordisk Cut Patient Documentation From Months to Minutes. Now It Wants Claude to Speed Drug Research

The Danish pharmaceutical company is best known for the weight-loss drug Wegovy. Its latest partnership aims to find the next groundbreaking treatment.

Novo Nordisk open to direct New York listing, CEO Doustdar tells FT

BioInnovation Institute Selects 17 European Startups for Funding and Support

Insider Brief PRESS RELEASE — Following the announcement of a new EUR 736M from the Novo Nordisk Foundation to the BioInnovation Institute (BII), the Danish innovation house made i...

Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.

Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

Novo will test Anthropic’s Claude Science to speed up drug discovery

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic dise...

<![CDATA[Novo Announces Drug Discovery Collaboration with Anthropic ]]>

Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billi...

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

Bodø/Glimt inngår samarbeid med omstridt medisinselskap

Norges beste fotballklubb inngår samarbeid med Novo Nordisk, selskapet bak slankemiddelet Ozempic.

Ozempic-maker Novo Nordisk slims down to ‘Novo’

Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced on Monday a name change to just Novo, hoping it will be more “memorable and rele...

Novo partners with Orbis, deepening investment in oral peptide drugs

The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.